This is a preview of subscription content, log in via an institution to check access.
Notes
2019 euros
Reference
Visser LA, et al. The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-beta1a Therapy Versus Injectable Interferon-beta1a Treatment in Relapsing-Remitting Multiple Sclerosis. PharmacoEconomics : 4 Sep 2021. Available from: URL: http://doi.org/10.1007/s40273-021-01081-y
Rights and permissions
About this article
Cite this article
Bioelectronic implant delivering interferon-β1a cost effective for RRMS. PharmacoEcon Outcomes News 887, 7 (2021). https://doi.org/10.1007/s40274-021-08023-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08023-2